ЛІТЕРАТУРА

1. Allegra CJ, Jessup JM, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009;27 (12):2091-2096.
2. US Food and Drug Administration. Cetuximab (Erbitux) and panitumumab (Vectibix). http://www .fda.gov/AboutFDA/CentersOffices/CDER /ucm172905.htm. Accessed March 29, 2010.
3. European Medicines Agency. Questions and answers on the marketing authorisation for Vectibix. September 20, 2007. http://www.emea.europa.eu /pdfs/human/opinion/40511307en.pdf. Accessed March 29, 2010.
4. European Medicines Agency. Committee for Medicinal Products for Human Use postauthorisation summary of positive opinion for Erbitux. May 30, 2008. http://www.emea.europa.eu/pdfs/human/opinion /erbitux_28040208en.pdf. Accessed March 29, 2010.
5. Wellcome Trust Sanger Institute. Catalogue of somatic mutations in cancer. http://www.sanger .ac.uk/genetics/CGP/cosmic/. Accessed January 15, 2010.
6. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 2007;67(6):2643- 2648.
7. Frattini M, Saletti P, Romagnani E, et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer. 2007; 97(8):1139-1145.
8. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6(5):279-286.
9. Lee CN, Chen HY, Liu HE. Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations. J Clin Oncol. 2010;28 (7):e111-e112.
10. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508-515.
11. Guerrero S, Casanova I, Farre´ L, Mazo A, Capellà G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60(23):6750-6756.
12. Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007;357(20):2040-2048.
13. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359(17):1757-1765.
13. Tejpar S, Peeters M, Humblet Y, et al. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data. J Clin Oncol. 2007; 25(18S):4037.
14. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337-345.
15. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol. 2006;24(30):4914-4921.
16. Wilke H, Glynne-Jones R, Thaler J, et al. MABEL— a large multinational study of cetuximab plus irinotecan in irinotecan resistant metastatic colorectal cancer. J Clin Oncol. 2006;24(18S):3549.
17. Pessino A, Artale S, Sciallero S, et al. First-line singleagent cetuximab in patients with advanced colorectal cancer. Ann Oncol. 2008;19(4):711-716.
18. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(10):1626-1634.
19. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360 (14):1408-1417.
20. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009;27 (5):663-671.
21. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563-572.
22. Di Nicolantonio F, Arena S, Gallicchio M, et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutationspecific drug responses. Proc Natl Acad SciUSA. 2008; 105(52):20864-20869.